FrançaisAre analysts right about ADMA Biologics, Inc. (ADMA)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For ADMA Biologics, Inc., we replayed every analyst price target of the past 12 months and measured the real outcome: 55% were profitable, average return +71% (51 calls). At 3 months: +14% average return (53% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| HC Wainwright & Co. | 18 | 67% | +96% |
| Raymond James | 11 | 46% | +45% |
| Cantor Fitzgerald | 9 | 67% | +113% |
| Mizuho | 6 | 83% | +102% |
Frequently asked questions
Is ADMA Biologics, Inc. a buy right now?
The analyst consensus on ADMA Biologics, Inc. (ADMA) is "Buy" (5 bullish, 0 bearish calls over 12 months). This is not advice: historically, 55% of their targets on this stock turned out profitable over 1 year.
What is ADMA Biologics, Inc.'s price target?
The median 12-month price target is $17.50 (+85% vs $9.48), ranging from $17.00 to $18.00 (2 analysts).
Are analysts accurate on ADMA Biologics, Inc.?
Over 1 year, 55% of analyst targets on ADMA Biologics, Inc. were profitable, for an average return of +71% (across 51 timestamped calls). This is JPI Invest's accuracy metric.
What is the ADMA Biologics, Inc. stock forecast?
Analysts target a median of $17.50 within 12 months, i.e. +85% vs the current price. The most bullish targets $18.00, the most cautious $17.00.
What is the ADMA Biologics, Inc. stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $17.50, +85%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (55%), and the stock's past trajectory.
Is ADMA Biologics, Inc. overvalued?
Detailed valuation data for ADMA Biologics, Inc. is available in the interactive analysis.
📊 See the full interactive analysis of ADMA Biologics, Inc. →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.